|View printer-friendly version|
Presentation topics include:
• BioTime’s Products in Development Addressing the Large and Growing Markets in Age-Related Degenerative Disease; and
• New Insights into the Fundamental Biology of Human Aging
Dr. West’s presentation is titled “Applied Gerontology: The Regenerative Medicine Revolution” and describes the application of
The four-day conference features scientific leaders from around the world to discuss recent breakthroughs in understanding the aging process, as well as companies and institutions focused on applying the technologies to human aging.
More information on the conference is available at ivaoconf.com.
Background on Regenerative Medicine and Aging
Age-related degenerative diseases are commonly associated with the loss or dysfunction of the cells in various tissues of the body. The clocking mechanism for these changes may be the fact that human cells have a finite capacity to replicate themselves in response to injury, a phenomenon called the “Hayflick Limit.” Dr. West led the effort in the mid-1990s that led to the identification of the immortalizing gene called “telomerase” that could rewind the clock of cellular aging in human cells. Indeed, the administration of telomerase allows human cells to escape the Hayflick limit and replicate indefinitely, a phenomenon designated “cell immortalization.”
Since that time,
In order to efficiently advance product candidates through the clinical trial process, we have historically created operating subsidiaries for each program and product line. This approach has fostered efficient use of resources and reduced shareholder dilution as compared to strategies commonly deployed by the biotechnology industry, as the various programs and product lines have advanced through basic research and animal studies. We and our subsidiaries now have four therapeutic product candidates in human clinical trials, each of which addresses a large market opportunity. In addition to the development of therapeutics, BioTime’s research and other activities have resulted, over time, in the creation of other subsidiaries that address other non-therapeutic market opportunities such as cancer diagnostics, drug development and cell research products, and mobile health software applications.
Statements pertaining to future financial and/or operating results, future growth in research, technology, clinical development, and potential opportunities for
To receive ongoing
Dan L. Lawrence, 510-775-0510
EVC Group, Inc.
Michael Polyviou, 646-445-4800
Gotham Communications, LLC
Bill Douglass, 646-504-0890